In a 4-year-old child with facial edema, urinary tract infection, nephrotic-range proteinuria (urine protein‑to‑creatinine ratio 2.1 g/g) and severe thrombocytopenia, what is the recommended urgent evaluation and management?

Urgent Evaluation for Atypical Hemolytic Uremic Syndrome (aHUS)

This 4-year-old requires immediate evaluation for atypical hemolytic uremic syndrome (aHUS) or other thrombotic microangiopathy (TMA), given the triad of nephrotic-range proteinuria, severe thrombocytopenia, and facial edema in the context of a UTI.

Critical Immediate Actions

Urgent Laboratory Assessment

• Complete blood count with peripheral smear to assess for microangiopathic hemolytic anemia (schistocytes, helmet cells)
• Hemolysis markers: LDH (elevated), haptoglobin (decreased), indirect bilirubin (elevated), reticulocyte count (elevated)
• Renal function: serum creatinine, BUN, electrolytes
• Coagulation studies: PT, PTT, fibrinogen, D-dimer to differentiate from DIC
• Direct Coombs test (should be negative in TMA)
• Complement levels: C3, C4, CH50 (may be low in complement-mediated aHUS)

Assess for TMA Diagnostic Criteria

The combination of:

• Thrombocytopenia (severe in this case)
• Microangiopathic hemolytic anemia (must confirm on smear)
• Acute kidney injury with proteinuria

If schistocytes are present with hemolysis markers, this constitutes a medical emergency requiring nephrology consultation within hours, not days.

Differential Diagnosis Priority

Primary Concern: Thrombotic Microangiopathy

• Atypical HUS: Can be triggered by infections including UTI; complement-mediated podocyte injury explains nephrotic-range proteinuria
• Shiga toxin-producing E. coli HUS (STEC-HUS): Less likely without bloody diarrhea, but stool culture for STEC should be sent
• Secondary TMA: Drug-induced, infection-associated

Alternative Considerations

• Severe nephrotic syndrome with complications: While nephrotic syndrome causes thrombotic risk 1, severe thrombocytopenia is unusual and suggests consumption rather than hypercoagulability
• Immune thrombocytopenic purpura (ITP) with concurrent nephrotic syndrome: Possible but less likely given the clinical context
• Dengue or other viral hemorrhagic fever: Consider if travel history present 2

Management Algorithm

If TMA Confirmed (schistocytes + hemolysis + thrombocytopenia + AKI):

Immediate interventions:

• Nephrology consultation emergently (same day)
• Avoid platelet transfusions unless life-threatening bleeding (can worsen TMA)
• Maintain euvolemia carefully - avoid aggressive fluid resuscitation that could worsen edema, but ensure adequate perfusion
• Consider eculizumab (complement C5 inhibitor) for aHUS after meningococcal vaccination or antibiotic prophylaxis
• Plasma exchange/plasma infusion may be initiated while awaiting genetic testing results for complement abnormalities

If TMA Excluded:

Evaluate for primary nephrotic syndrome with complications:

• Genetic testing for congenital/infantile nephrotic syndrome genes (NPHS1, NPHS2, WT1, PLCE1) 1
• Renal biopsy consideration if genetic testing negative and no contraindication from thrombocytopenia
• Infection screening: TORCH titers, syphilis serology, hepatitis B/C if congenital nephrotic syndrome suspected 1
• Anti-NEP antibodies if mother has history of pregnancy losses or family history suggestive 1

Critical Pitfalls to Avoid

1. Do not assume this is simple nephrotic syndrome: The severe thrombocytopenia is a red flag requiring immediate TMA evaluation
2. Do not give platelet transfusions empirically: If TMA present, this can precipitate thrombotic events
3. Do not delay complement studies: These must be drawn before any plasma products are given
4. Do not treat UTI as isolated finding: It may be a trigger for underlying complement dysregulation in aHUS
5. Do not start immunosuppression (steroids, calcineurin inhibitors) until genetic causes excluded, as most congenital nephrotic syndrome is steroid-resistant 1

Supportive Care During Evaluation

• Treat UTI appropriately with culture-directed antibiotics
• Monitor for complications of nephrotic syndrome: thrombosis (though paradoxical with thrombocytopenia), infections, hypovolemia 1
• Careful fluid management: Assess for intravascular volume status - peripheral perfusion, blood pressure, urine output
• Avoid nephrotoxic agents: NSAIDs, aminoglycosides
• Albumin infusions only if severe hypovolemia with hemodynamic compromise; give with furosemide 0.5-1 mg/kg at end of infusion 1

Prognosis Considerations

If aHUS is confirmed, mortality and morbidity are high without prompt treatment with complement blockade. Early eculizumab initiation (within 24-48 hours) significantly improves renal outcomes. If this represents congenital nephrotic syndrome with severe complications, patients are prone to thromboses, infections, and progression to kidney failure 1, requiring multidisciplinary management at a pediatric nephrology center.

The key is rapid peripheral smear examination and hemolysis workup to rule in or rule out TMA - this determines whether the child needs emergency complement-directed therapy versus management of complicated nephrotic syndrome.